Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F. Kelley, Renu Singh, Paul Benson et al.|New England Journal of Medicine|2024Cited by 260
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept studyJoseph J. Eron, Marina Caskey, Susan J. Little et al.|The Lancet HIV|2024Cited by 47